Endocrine approaches in the therapy of prostate carcinoma

Human Reproduction Update

Volumn 11, Issue 3, 2005, Pages 309-317

  d'Ancona, F C H ^a   Debruyne, F M J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen receptor modification; Antiandrogens; Hormonal therapy; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANANDRONE; ANDROGEN; ANTIANDROGEN; ANTIESTROGEN; AROMATASE INHIBITOR; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; FLUTAMIDE; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; NILUTAMIDE; TAMOXIFEN; TESTOSTERONE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HORMONE ACTION; HORMONE INHIBITION; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER TOXICITY; MASTALGIA; METASTASIS; MONOTHERAPY; NAUSEA; ORCHIECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; WASTING SYNDROME;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CLINICAL TRIALS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 18744412654     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/dmi004     Document Type: Review

References (75)

1. Bazinet M, Zheng W, Begin LR, Aprikian AG, Karakiewicz PI and Elhilali MM (1997) Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 49, 721-725.
2. Blackard CE (1975) The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer Chemother Rep 59,225-227.
3. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U et al. (1999) Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 17,2027-2038.
4. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C et al. (1997) Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 32,391-395.
5. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360,103-106.
6. Byar DP (1973) Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32,1126-1130.
7. Byar DP and Corle DK (1988) Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr,165-170.
8. Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, Blute ML and Bostwick DG (1998) Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 22,1491-1500.
9. Crook JM, Szumacher E, Malone S, Huan S and Segal R (1999) Intermittent androgen suppression in the management of prostate cancer. Urology 53,530-534.
10. Debruyne F (2002) Hormonal therapy of prostate cancer. Semin Urol Oncol 20,4-9.
11. Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G and Giuliani L (1991) Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 146, 377-381.
12. Denis L, Debruyne F, De Porre P and Bruynseels J (1998) Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer. Eur J Cancer 34,469-475.
13. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M and Suciu S (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135,303-307.
14. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, Mcleod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Jr et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 339,1036-1042.
15. European Study Group (2000) 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38, 706-713.
16. Fourcade, R.O., Chatelain, C., and Poterre, M. (1998) An open multicentre study to compare the effect and safety of casodex (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol 33 (Suppl 1) 88 Abstract 349.
17. Frazier HA, Robertson JE, Humphrey PA and Paulson DF (1993) Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 149,516-518.
18. Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N and Sullivan LD (1997) Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. J Urol 157,1727-1730.
19. Gleave, M.E., La Bianca, S.E., Goldenberg, S.L., Jones, E.C., Bruchovsky, N., and Sullivan, L.D. (2000a) Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 1; 56 (2) 289-294.
20. Gleave ME, La Bianca S and Goldenberg SL (2000b) Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls. Prostate Cancer Prostatic Dis b3,136-144.
21. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD and Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45,839-844.
22. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ et al. (1996) Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 156,873-877.
23. Granfors T, Modig H, Damber JE and Tomic R (1998) Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 159,2030-2034.
24. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR and Small EJ (2001) Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 58,240-245.
25. Higano CS, Ellis W, Russell K and Lange PH (1996) Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48,800-804.
26. Horwich A, Huddart RA, Gadd J, Boyd PJ, Hetherington JW, Whelan P and Dearnaley DP (1998) A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 81,96-99.
27. Huggins C and Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1, 293-297.
28. Hugosson J, Abrahamsson PA, Ahlgren G, Aus G, Lundberg S, Schelin S, Schain M and Pedersen K (1996) The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 29,413-419.
29. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K and Melezinek I (2000) Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 63 years of follow up. J Urol 164, 1579-1582.
30. Jones EC (1990) Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 144,89-93.
31. Kaisary AV, Iversen P, Tyrrell CJ, Carroll K and Morris T (2001) Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis 4,196-203.
32. Klotz LH, Herr HW, Morse MJ and Whitmore WF, Jr (1986) Intermittent endocrine therapy for advanced prostate cancer. Cancer 58,2546-2550.
33. Kolvenbag GJ, Iversen P and Newling DW (2001) Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 58,16-23.
34. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM and Dahan R (1989) Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). New Engl J Med 321,413-418.
35. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Belanger A and Candas B (1997) Neoadjuvant hormonal therapy: the Canadian experience. Urology 49,56-64.
36. Lee F, Siders DB, McHug TA, Solomon MH and Klamerus ML (1997) Long-term follow-up of stages T2-T3 prostate cancer pretreated. with androgen ablation therapy prior to radical prostatectomy. Anticancer Res 17,1507-1510.
37. Lieberman R (2001) Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology 58,83-90.
38. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED and Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. New Engl J Med 341,1781-1788.
39. Moffat LE (1990) Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 18 (Suppl 3), 26-27.
40. MRC Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79,235-246.
41. Murphy WM, Soloway MS and Barrows GH (1991) Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68,821-828.
42. Newling DW (2001) Early versus late androgen deprivation therapy in metastatic disease. Urology 58,50-55.
43. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T and Okuyama A (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89,2570-2576.
44. Oefelein MG (1998) Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 160,1685-1688.
45. Oefelein MG and Cornum R (2000) Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164,726-729.
46. Orlando M, Chacon M, Salum G and Chacon DR (2000) Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer. Ann Oncol 11,177-181.
47. Patterson SG, Balducci L and Pow-Sang JM (2002) Controversies surrounding androgen deprivation for prostate cancer. Cancer Control 9,315-325.
48. Pavone-Macaluso M (1994) Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicentre randomised study. SIU 23rd Congress
49. Pedraza R and Kwart AM (2003) Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression? Urology 61, 770-773.
50. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15,1013-1021.
51. Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim CS and Fine RL (1996) Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 88,908-917.
52. Rosen MA, Goldstone L, Lapin S, Wheeler T and Scardino PT (1992) Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148,331-337.
53. Rosenbaum E, Wygoda M, Gips A. et al (2000) Diethylstilbestrol is an active agent in prostate cancer patients after failure to complete androgen blockade. 19,349a
54. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ and Aronson N (2002) Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95,361-376.
55. Schröder FH, Collette L, de Reijke TM and Whelan P (2000) Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group European Organization for Research and Treatment of Cancer. Br J Cancer 82,283-290.
56. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R and Di Silverio F (2003) Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 55,168-179.
57. Serels S and Melman A (1998) Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation. J Urol 159,1309.
58. Shadidi M, Norman AR and Gadd J (2001) Prospective review of diethylstilbestrol in advanced prostate cancer no longer responding to androgen suppression. Am Soc Clin Oncol,20.
59. Sharifi R, Knoll LD, Smith J and Kramolowsky E (1998) Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology 51,271-276.
60. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M and Pienta KJ (1998) A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 52,257-260.
61. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Jr and Puras-Baez A (1995) Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154,424-428.
62. Staiman VR and Lowe FC (1997) Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology 50,929-933.
63. Stricker HJ (2001) Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 58,24-25.
64. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN and Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl J Med 332, 1393-1398.
65. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B and Balk SP (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59, 2511-2515.
66. Thompson IM, Zeidman EJ and Rodriguez FR (1990) Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 144,1479-1480.
67. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC and O'Boyle PJ (1996) A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 29,47-54.
68. Tilley WD, Buchanan G, Hickey TE and Bentel JM (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2,277-285.
69. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M and Garnick MB (2001) The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165,1585-1589.
70. Trapasso JG, deKernion JB, Smith RB and Dorey F (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152,1821-1825.
71. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A and Blackledge G (1998a) A randomised comparison of 'Casodex' (bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33,447-456.
72. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K and Cockshott ID (1998b) Casodex 10-200mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies Casodex Study Group. Eur Urol 33,39-53.
73. Van Andel G and Kurth KH (2003) The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 44,209-214.
74. Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde, Werbrouck P, Ackaert K, Oyen R, Pittomvils G and Baert L (1995) Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 154,429-434.
75. Wysowski DK and Fourcroy JL (1996) Flutamide hepatotoxicity. J Urol 155,209-212.